Board of Directors
Since 2019, Margaret has been the CFO of Macrophage Pharma Ltd.
Margaret is a Chartered Management Accountant with over 24 years’ experience covering a number of sectors but particularly in Life Sciences. In addition to MPL, Margaret supports several other Biotech companies which include GammaDelta Therapeutics Ltd, Storm Therapeutics Ltd, Adaptate Biotherapeutics and Leucid Bio Ltd.
Prior to co-founding Bradshaw Daniel Ltd in 2012, Margaret worked in both international and UK group companies and held the position of Finance Director at Camlab Limited.
Margaret holds a certificate in Company Direction from the Institute of Directors and a degree at The Chartered Institute of Management Accountants.
Dr Reddy joined Macrophage Pharma in January 2020 with over 15 years of experience in the biopharmaceutical industry. He was previously at Glenmark Pharmaceuticals where he was a senior vice president and global head of translational sciences leading the translational programmes of the Company’s innovative preclinical and clinical portfolio. He co-founded APC Therapeutics Inc., a small molecule immuno-oncology startup, the lead programme of which was licensed to Glenmark. Previously, Dr Reddy acted as a senior director of strategic partnerships at Pfizer’s Center for Therapeutic Innovation.
Prior to that he held roles with Sanofi, as head of bio-innovation and as global head of oncology target discovery where he was involved in target identification and validation (TIDVAL) function and progression of multiple programmes from preclinical to clinical trials. Before joining Sanofi, Dr Reddy was a group leader in oncology drug discovery at the Novartis Institute for Functional Genomics, San Diego. He received his PhD in human biology at Ludwig Maximilians Universität, Munich and completed a post-doctoral fellowship in oncology and immunology at Scripps Research Institute, La Jolla.
Dr Parker is a business development professional with over 20 years’ experience of R&D and commercialisation of innovative research through licensing and spin-outs.
Dr Parker joined Macrophage Pharma in July 2017, from a Business Development Executive role at Cancer Research Technology Ltd (CRT), the development and commercialisation arm of Cancer Research UK, and served as a non-executive Director of cancer diagnostic company Arquer Ltd and cancer therapeutic company Azeria Therapeutics Ltd.
Prior to joining CRT, Dr Parker was Head of Research at KS Biomedix, a UK quoted Biopharmaceutical company developing therapeutic antibodies for cancer and inflammation.
Dr Parker holds an MSc in Molecular Biology and a PhD from the Medical Faculty, Lund University, Sweden where she elucidated the molecular effects of mutations that arise in coagulation factor V and give rise to venous thrombosis.
Dr Moffat joined Macrophage Pharma in November 2014. He had previously been Director of Chemistry at Chroma Therapeutics from 2004 to 2012 having played a leading role in the discovery and development of the Esterase Sensitive Motif technology platform. During this period three molecules from his chemistry team were progressed to the clinic including the macrophage targeted histone deacetylase inhibitors CHR-2845 and CHR-5154. His was also Head of Chemistry at Celltech from 2001 to 2004, prior to its acquisition by UCB, having begun his industrial career there in 1989.
He holds a BSc and PhD from the University of Glasgow. He has extensive experience in oncology and inflammation preclinical research, having led groups which have identified numerous clinical development candidates in these therapeutic areas. He is the author and inventor on more than 60 patents and publications.